Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Christopher A. Rabiola"'
Autor:
Gabrielle P. Dailey, Christopher A. Rabiola, Gangjun Lei, Junping Wei, Xiao-Yi Yang, Tao Wang, Cong-Xiao Liu, Melissa Gajda, Amy C. Hobeika, Amanda Summers, Robert D. Marek, Michael A. Morse, Herbert K. Lyerly, Erika J. Crosby, Zachary C. Hartman
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
ABSTRACTER+ breast cancers (BC) are characterized by the elevated expression and signaling of estrogen receptor alpha (ESR1), which renders them sensitive to anti-endocrine therapy. While these therapies are clinically effective, prolonged treatment
Externí odkaz:
https://doaj.org/article/e1e721b8aa614715a2839e38dfea6881
Autor:
Li-Chung Tsao, Erika J. Crosby, Timothy N. Trotter, Junping Wei, Tao Wang, Xiao Yang, Amanda N. Summers, Gangjun Lei, Christopher A. Rabiola, Lewis A. Chodosh, William J. Muller, Herbert Kim Lyerly, Zachary C. Hartman
Publikováno v:
JCI Insight, Vol 7, Iss 6 (2022)
Two HER2-specific mAbs, trastuzumab and pertuzumab (T+P), combined with chemotherapy comprise standard-of-care treatment for advanced HER2+ breast cancers (BC). While this antibody combination is highly effective, its synergistic mechanism-of-action
Externí odkaz:
https://doaj.org/article/c87d5137315e42528a934056270a6891
Autor:
Zachary C. Hartman, Herbert K. Lyerly, Michael A. Morse, Jeremy Force, Joshua C. Snyder, Benjamin G. Vincent, Benjamin K. Ashby, Shengjie Chai, Charles M. Perou, Xiaping He, Daniel P. Hollern, Jonathan H. Shepherd, Terry Hyslop, Gloria Broadwater, Lewis A. Chodosh, William J. Muller, Kay U. Wagner, Cong-Xiao Liu, Tao Wang, Xiao-Yi Yang, Jun-Ping Wei, Gangjun Lei, Christopher A. Rabiola, Anthony-Fayez Haddad, Chaitanya R. Acharya, Erika J. Crosby
Supplementary Figure 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04d9f7fafcbe4db7fdd5257499cd6572
https://doi.org/10.1158/1078-0432.22477275
https://doi.org/10.1158/1078-0432.22477275
Autor:
Zachary C. Hartman, Herbert K. Lyerly, Michael A. Morse, Jeremy Force, Joshua C. Snyder, Benjamin G. Vincent, Benjamin K. Ashby, Shengjie Chai, Charles M. Perou, Xiaping He, Daniel P. Hollern, Jonathan H. Shepherd, Terry Hyslop, Gloria Broadwater, Lewis A. Chodosh, William J. Muller, Kay U. Wagner, Cong-Xiao Liu, Tao Wang, Xiao-Yi Yang, Jun-Ping Wei, Gangjun Lei, Christopher A. Rabiola, Anthony-Fayez Haddad, Chaitanya R. Acharya, Erika J. Crosby
Supplementary Table 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aeead83f5865375b9ce73a6c708588f
https://doi.org/10.1158/1078-0432.22477263
https://doi.org/10.1158/1078-0432.22477263
Autor:
Zachary C. Hartman, Herbert K. Lyerly, Michael A. Morse, Jeremy Force, Joshua C. Snyder, Benjamin G. Vincent, Benjamin K. Ashby, Shengjie Chai, Charles M. Perou, Xiaping He, Daniel P. Hollern, Jonathan H. Shepherd, Terry Hyslop, Gloria Broadwater, Lewis A. Chodosh, William J. Muller, Kay U. Wagner, Cong-Xiao Liu, Tao Wang, Xiao-Yi Yang, Jun-Ping Wei, Gangjun Lei, Christopher A. Rabiola, Anthony-Fayez Haddad, Chaitanya R. Acharya, Erika J. Crosby
Purpose:Despite promising advances in breast cancer immunotherapy, augmenting T-cell infiltration has remained a significant challenge. Although neither individual vaccines nor immune checkpoint blockade (ICB) have had broad success as monotherapies,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76c78a9a45a6376562600743e9c01e68
https://doi.org/10.1158/1078-0432.c.6529605.v1
https://doi.org/10.1158/1078-0432.c.6529605.v1
Autor:
Zachary C. Hartman, Herbert K. Lyerly, Michael A. Morse, Jeremy Force, Joshua C. Snyder, Benjamin G. Vincent, Benjamin K. Ashby, Shengjie Chai, Charles M. Perou, Xiaping He, Daniel P. Hollern, Jonathan H. Shepherd, Terry Hyslop, Gloria Broadwater, Lewis A. Chodosh, William J. Muller, Kay U. Wagner, Cong-Xiao Liu, Tao Wang, Xiao-Yi Yang, Jun-Ping Wei, Gangjun Lei, Christopher A. Rabiola, Anthony-Fayez Haddad, Chaitanya R. Acharya, Erika J. Crosby
Supplementary methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f90129615fc3bcb3641865d50082013
https://doi.org/10.1158/1078-0432.22477266.v1
https://doi.org/10.1158/1078-0432.22477266.v1
Autor:
Zelanna Goldberg, Christian Maine, Gabrielle P. Dailey, Christine Domingo, Gaelle Picarda, Hunter Little, Annie Chou, Jessica Sparks, Darina Spasova, Shigeki Miyake-Stoner, Zachary C. Hartman, Christopher A. Rabiola, Erika J. Crosby, Herbert K. Lyerly, Nathaniel Wang, Parinaz Aliahmad
Publikováno v:
Cancer Research. 83:6403-6403
Drug resistance remains the major driving factor behind the clinical failure of targeted therapeutics. Current oncology precision medicine approaches rely on targeting known acquired resistance mutations, such as EGFR T790M or ALK/ROS mutations in NS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4aab0eddc63838b68b21f9c6895c62ca
https://doi.org/10.1158/1538-7445.am2023-6403
https://doi.org/10.1158/1538-7445.am2023-6403
Autor:
Li-Chung Tsao, Erika J. Crosby, Timothy N. Trotter, Junping Wei, Tao Wang, Xiao Yang, Amanda N. Summers, Gangjun Lei, Christopher A. Rabiola, Lewis A. Chodosh, William J. Muller, Herbert Kim Lyerly, Zachary C. Hartman
Publikováno v:
JCI insight. 7(6)
Two HER2-specific mAbs, trastuzumab and pertuzumab (T+P), combined with chemotherapy comprise standard-of-care treatment for advanced HER2+ breast cancers (BC). While this antibody combination is highly effective, its synergistic mechanism-of-action
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f255addfe7374a3f5176d52c982f21fb
https://pubmed.ncbi.nlm.nih.gov/35167491
https://pubmed.ncbi.nlm.nih.gov/35167491
Autor:
Herbert Kim Lyerly, Daniel P. Hollern, Kay U. Wagner, Anthony-Fayez Haddad, Erika J. Crosby, William J. Muller, Chaitanya R. Acharya, Gloria Broadwater, Michael A. Morse, Xiaping He, Junping Wei, Shengjie Chai, Charles M. Perou, Lewis A. Chodosh, Tao Wang, Terry Hyslop, Joshua C. Snyder, Gangjun Lei, Benjamin G. Vincent, Jonathan Shepherd, Christopher A. Rabiola, Cong-Xiao Liu, Jeremy Force, Benjamin K. Ashby, Zachary C. Hartman, Xiao Yi Yang
Publikováno v:
Clin Cancer Res
Purpose: Despite promising advances in breast cancer immunotherapy, augmenting T-cell infiltration has remained a significant challenge. Although neither individual vaccines nor immune checkpoint blockade (ICB) have had broad success as monotherapies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::757b563486bd40adafe3f237d45d1c1a
https://europepmc.org/articles/PMC7483405/
https://europepmc.org/articles/PMC7483405/
Autor:
Erika J. Crosby, Zachary C. Hartman, William J. Muller, Benjamin K. Ashby, Jonathan Shepherd, Herbert Kim Lyerly, Lewis A. Chodosh, Xiaping He, Michael A. Morse, Daniel P. Hollern, Gloria Broadwater, Charles M. Perou, Benjamin G. Vincent, Chaitanya R. Acharya, Christopher A. Rabiola
Publikováno v:
Cancer Research. 80:904-904
Despite promising advances, overcoming immune suppression and driving productive immune responses in the tumor microenvironment remains a significant challenge. Using a spontaneous breast cancer model, we found that vaccination targeting HER2d16, a h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af24f2056b739475acc0761e8e41d98b
https://doi.org/10.1158/1538-7445.am2020-904
https://doi.org/10.1158/1538-7445.am2020-904